GlassScriptPhysician profile
David A Ross
NPI 1689011272
$1,699.26
in general payments reported to CMS, 2019-2025
24 companies · $194 in 2025
The $194 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $496 · 2020: $317 · 2021: $118 · 2022: $112 · 2023: $194 · 2024: $268 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $656.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $221.35 | 2022-2025 | Farxiga, Breztri |
| Pacira Therapeutics, INC. | $216.25 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.31 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $134.66 | 2021-2025 | |
| Mannkind Corporation | $124.99 | 2019 | |
| Eisai INC. | $116.49 | 2019 | |
| Lilly USA, LLC | $115.53 | 2020-2023 | Emgality, Jardiance, Mounjaro |
| Novo Nordisk INC | $86.82 | 2020-2024 | Ozempic, Rybelsus, Wegovy |
| Allergan, INC. | $74.55 | 2019-2021 | |
| Depuy Synthes Sales INC. | $68.01 | 2023-2025 | Peak, Orthovisc |
| Abbott Laboratories | $66.08 | 2024-2025 | Freestyle Libre 3 |
| Baxter Healthcare | $56.83 | 2022-2025 | Hillrom - Carnation Ambulatory Monitor |
| Kowa Pharmaceuticals America, INC. | $56.27 | 2019-2021 | |
| Amgen INC. | $30.57 | 2019-2023 | Repatha |
| Abbvie INC. | $28.36 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spectrum Pharmaceuticals INC. | $22.23 | 2025 | Rolvedon |
| Ibsa Pharma INC. | $21.05 | 2023 | Tirosint, Licart |
| Avanir Pharmaceuticals, INC. | $19.46 | 2020 | |
| Glaxosmithkline, LLC. | $19.36 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $18.60 | 2024 | Zilretta, Iovera |
| Sanofi Pasteur INC. | $18.11 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.41 | 2020 | |
| Amarin Pharma, INC. | $14.11 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.86 | 2023 | Piqray, Kisqali |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.